TickerFacts.

Stoke Therapeutics, Inc. (STOK): Revenue

Annual figures by period end, from SEC filings.

$184.42M
Year ended 2025-12-31
$27.59M
Trailing 12 months to 2026-06-30
+145.9%
3-year compound annual growth
2022-12-31: $12.40M2023-12-31: $8.78M2024-12-31: $36.55M2025-12-31: $184.42M$184.42M
2022-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$184.42M+404.5%2026-03-16, From 2025-01-01
2024-12-31$36.55M+316.3%2026-03-16, From 2024-01-01
2023-12-31$8.78M-29.2%2025-03-18, From 2023-01-01
2022-12-31$12.40Mn/a2024-03-25, From 2022-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Stoke Therapeutics, Inc. (STOK)2025-12-31$184.42M+404.5%
Maravai Lifesciences Holdings, Inc. (MRVI)2025-12-31$185.74M-28.3%
Lifevantage Corp (LFVN)2026-06-30$182.59M-20.1%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$189.76M+45.8%
Cryoport, Inc. (CYRX)2025-12-31$176.18M+12.4%
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$175.11M+216.9%
Syndax Pharmaceuticals Inc (SNDX)2025-12-31$172.35M+627.8%
Amarin Corp PLC (AMRN)2025-12-31$213.65M-6.5%
Liquidia Corp (LQDA)2025-12-31$158.32Mn/m

Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗